After entering the ophthalmology industry “by accident,” Bernhard Günther founded Novaliq in 2004 to pursue therapeutic applications for CyclASol, a novel solution used in drug delivery. While Novaliq pursued other therapeutic applications initially, fate once again brought Günther back into ophthalmology. Today, the company is positioned to deliver two new treatments for dry eye disease. In this podcast we’ll cover the company’s origins, its unusual investor, and its move to the US.